CST, 92445S, FKBP10 Antibody

Polyclonal Antibody for studying FKBP10. Validated for Western Blotting. Highly specific and rigorously validated in-house, FKBP10 Antibody (CST #92445) is ready to ship. Product Usage Information Western Blotting: 1:1000 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting Specificity / Sensitivity FKBP10 Antibody recognizes endogenous levels of total FKBP10 protein. Species Reactivity: Human Source / Purification Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro425 of human FKBP10 protein. Antibodies are purified by peptide affinity chromatography. Background FK506-binding proteins (FKBPs) are a large family of conserved proteins characterized by the presence of one or more peptidyl-prolyl cis-trans isomerase (PPIase) domains. The founding member FKBP12 was originally identified as a non-covalent binding protein of FK506 and rapamycin, two widely used immunosuppressive drugs, and mediated their immunosuppressive activity. The FKBP12-FK506 complex specifically targets the Ca -dependent serine-threonine phosphatase calcineurin, and the FBKP12-rapamycin complex acts on mTOR (mammalian target of rapamycin). While both FK506 and rapamycin bind to the PPIase domain and inhibit PPIase activity of FKBP12, the inhibition of PPIase activity per se does not contribute to their immunosuppressive activity. Some members of the FKBP family also contain other functional domains or motifs. FKBPs have been reported to play roles in diverse processes such as protein folding, cellular signaling, and transcription, and have been implicated in several diseases (1-3). FKBP10, also known as FKBP65 (65 kDa FK506-binding protein), has four tandem PPIase domains and is an endoplasmic reticulum (ER) resident protein, where it modulates the folding and trafficking of secretory proteins. FKBP10 plays an important role in collagen folding and secretion and its mutation is associated with osteogenesis imperfecta (4-6), and it is considered as a therapeutic target for idiopathic pulmonary fibrosis (IPF) (7,8). Recent reports suggest that FKBP10 may be a biomarker or therapeutic targets for several different cancers (9-11). Alternate Names 65 kDa FK506-binding protein; 65 kDa FKBP; BRKS1; FK506 binding protein 10, 65 kDa; FK506-binding protein 10; FKB10; FKBP prolyl isomerase 10; FKBP-10; FKBP-65; FKBP10; FKBP65; FLJ20683; FLJ22041; FLJ23833; hFKBP65; Immunophilin FKBP65; OI11; OI6; Peptidyl-prolyl cis-trans isomerase FKBP10; PPIASE; PPIase FKBP10; Rotamase Specification REACTIVITY: H SENSITIVITY: Endogenous MW (kDa): 78 SOURCE: Rabbit